1 Result(s)

Article

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial

New immuno-oncology therapies targeting programmed cell death receptor 1 (PD-1) have improved patient outcomes in a broad range of cancers. The objective of this analysis was to evaluate the PK, pharmacodynami...

Amita Patnaik, Glen J. Weiss, Drew W. Rasco… in Cancer Chemotherapy and Pharmacology (2022)